Articles
Page 13 of 20
-
Citation: BMC Pharmacology 2007 7(Suppl 2):A76
-
Use of human-derived cell lines for the investigation of dietary factors which affect DNA stability
Citation: BMC Pharmacology 2007 7(Suppl 2):A74 -
The potential antimutagenic and antioxidant effects of Maillard reaction products used as "natural antibrowning" agents
Citation: BMC Pharmacology 2007 7(Suppl 2):A72 -
iNOS expression and levels of nitric oxide in a hepatocarcinogenesis model of p47-NADPH knockout mice
Citation: BMC Pharmacology 2007 7(Suppl 2):A68 -
Ion channels alteration in dilated cardiomyopathy in human heart
Citation: BMC Pharmacology 2007 7(Suppl 2):A51 -
The role of cannabinoid CB1 receptor agonists in gastric mucosal protection in rats and mice
Citation: BMC Pharmacology 2007 7(Suppl 2):A47 -
14-Methoxy-metopon: a highly potent μ opioid agonist on rat vas deferens
Citation: BMC Pharmacology 2007 7(Suppl 2):A45 -
Electrophysiological characteristics of heart ventricular papillary muscles from histidine decarboxylase knockout and wild-type mice: effects of rosiglitazone
Citation: BMC Pharmacology 2007 7(Suppl 2):A43 -
Exploring the heterogeneity of use-dependent sodium channel inhibitor drugs. I: Fast- vs. slow-inactivated state preference
Citation: BMC Pharmacology 2007 7(Suppl 2):A41 -
Changes in the action of morphine challenge following perinatal morphine exposure in rats
Citation: BMC Pharmacology 2007 7(Suppl 2):A39 -
Ionotropic neurotransmitter receptors: activation and allosteric modulation
Citation: BMC Pharmacology 2007 7(Suppl 2):A37 -
P2 receptor-mediated modulation of noradrenaline release by electrical field stimulation and ischemic conditions in superfused rat hippocampus slices
Citation: BMC Pharmacology 2007 7(Suppl 2):A35 -
The basic difference in the pharmacological spectrum between methamphetamine and its derivative, the enhancer substance (-)-deprenyl
Citation: BMC Pharmacology 2007 7(Suppl 2):A33 -
Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation
Citation: BMC Pharmacology 2007 7(Suppl 2):A29 -
Experiments to localize the site for the anxiogenic action of NPY mediated by Y2 receptors in the mouse brain
Citation: BMC Pharmacology 2007 7(Suppl 2):A14 -
Mapping the interaction sites of the viral encoded chemokine receptor US28 and the sorting protein GASP-1
Citation: BMC Pharmacology 2007 7(Suppl 2):A12 -
Anticonvulsant and neuroprotective actions of endogenous dynorphin
Citation: BMC Pharmacology 2007 7(Suppl 2):A10 -
Selective serotonin reuptake inhibitors: a new modality for the treatment of lymphoma/leukaemia?
Citation: BMC Pharmacology 2007 7(Suppl 2):A8 -
Heterologous expression of membrane proteins in cardiac myocytes
Citation: BMC Pharmacology 2007 7(Suppl 2):A6 -
The hCMV chemokine receptor US28 prevents melanoma growth
Citation: BMC Pharmacology 2007 7(Suppl 2):A4 -
Restricted expression between parvalbumin and substance P receptor NK1 in interneurones of the lateral amygdala
Citation: BMC Pharmacology 2007 7(Suppl 2):A2 -
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Tuberous Sclerosis Complex (TSC) is an autosomal dominant hamartoma disorder with variable expression for which treatment options are limited. TSC is caused by a mutation in either the TSC1 or TSC2 genes, whose p...
Citation: BMC Pharmacology 2007 7:14 -
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
Using a human small cell lung cancer (SCLC) xenografted in nude mice, we have previously reported enhanced tumor growth inhibition following chemotherapy in combination with imatinib (STI571). We therefore invest...
Citation: BMC Pharmacology 2007 7:13 -
Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549)
Ciclesonide is a novel inhaled corticosteroid for the treatment of airway inflammation. In this study we investigated uptake and in vitro metabolism of ciclesonide in human alveolar type II epithelial cells (A549...
Citation: BMC Pharmacology 2007 7:12 -
Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7
Extracts from the rhizome of Cimicifuga racemosa (black cohosh) are increasingly popular as herbal alternative to hormone replacement therapy (HRT) for the alleviation of postmenopausal disorders. However, the mo...
Citation: BMC Pharmacology 2007 7:11 -
An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data
Protein-protein interactions (PPIs) are challenging but attractive targets for small chemical drugs. Whole PPIs, called the 'interactome', have been emerged in several organisms, including human, based on the ...
Citation: BMC Pharmacology 2007 7:10 -
Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences
The diuretic effect of valproates and its relation to urinary potassium (K+) and chloride (Cl-) excretion have not yet been investigated, so the aim of this study was to evaluate the influence of a single dose of...
Citation: BMC Pharmacology 2007 7:9 -
Activation of the cGMP/cGKI signalling pathway in primary murine VSMCs accelerates growth
Citation: BMC Pharmacology 2007 7(Suppl 1):P64 -
Analysis of cGKI inhibition by Rp-cGMP analogs
Citation: BMC Pharmacology 2007 7(Suppl 1):P62 -
Targeting the NO – cGMP pathway: phenotyping of NO-insensitive sGCbeta1 H105F knockin mice
Citation: BMC Pharmacology 2007 7(Suppl 1):P60 -
cGMP-dependent protein kinase regulates Rap1 signaling in platelets
Citation: BMC Pharmacology 2007 7(Suppl 1):P56 -
Abstract withdrawn
Citation: BMC Pharmacology 2007 7(Suppl 1):P54 -
Cysteine-rich protein 2 is a downstream effector of cGMP-dependent protein kinase I in nociception
Citation: BMC Pharmacology 2007 7(Suppl 1):P52 -
Increased aggregation of platelets lacking cGKI/PKG
Citation: BMC Pharmacology 2007 7(Suppl 1):S51 -
The use of PDE5 inhibitors in the treatment of benign prostate hyperplasia and lower urinary tract symptoms: preclinical evidences
Citation: BMC Pharmacology 2007 7(Suppl 1):P48 -
Novel GKAPs for cGMP-dependent protein kinase type II: identification and functional significance
Citation: BMC Pharmacology 2007 7(Suppl 1):S45 -
NO-sensitive guanylyl cyclase β1 subunit interacts with chromosomes during mitosis: novel role in the regulation of chromatin condensation
Citation: BMC Pharmacology 2007 7(Suppl 1):S43 -
Vascular remodelling in the absence and presence of cGKI
Citation: BMC Pharmacology 2007 7(Suppl 1):S41 -
A new Rac-cGMP signaling pathway
Citation: BMC Pharmacology 2007 7(Suppl 1):S39 -
Structural insights into sGC
Citation: BMC Pharmacology 2007 7(Suppl 1):S37 -
Design and synthesis of the first NO- and haem-independent sGC activator BAY 58–2667 for the treatment of acute decompensated heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):P25 -
Interstitial cells of Cajal in the urethra as effectors of the nitric oxide action through the cyclic GMP pathway
Citation: BMC Pharmacology 2007 7(Suppl 1):P23 -
BAY 58–2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers
Citation: BMC Pharmacology 2007 7(Suppl 1):P21 -
NO-induced motility effects in gastric fundus and pylorus of sGCβ1his105phe mutant mice
Citation: BMC Pharmacology 2007 7(Suppl 1):P15 -
The NO-cGMP axis in endothelial ischemia and ischemic preconditioning
Citation: BMC Pharmacology 2007 7(Suppl 1):S12 -
Molecular modulators of cardiac stress targeted by PDE5 inhibition
Citation: BMC Pharmacology 2007 7(Suppl 1):S6 -
Daily treatment with sildenafil, an inhibitor of cGMP-dependent phosphodiesterase, normalizes the exaggerated hemodynamic response to norepinephrine in fructose-fed rats
Citation: BMC Pharmacology 2007 7(Suppl 1):P5 -
LPS-induced down-regulation of NO-sensitive guanylyl cyclase in astrocytes occurs by proteasomal degradation in nuclear bodies
Citation: BMC Pharmacology 2007 7(Suppl 1):P3 -
Therapeutic potential of soluble guanylate cyclase agonists in pulmonary hypertension
Citation: BMC Pharmacology 2007 7(Suppl 1):S2 -
cGMP signaling pathway is involved in Leyding cell stress response
Citation: BMC Pharmacology 2007 7(Suppl 1):P1